1. Academic Validation
  2. Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats

Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats

  • J Ethnopharmacol. 2014 Feb 3;151(2):839-45. doi: 10.1016/j.jep.2013.11.039.
Xiu-Jun Wu 1 Meng-Liang Zhang 2 Xiang-Yong Cui 2 J Paul Fawcett 3 Jing-Kai Gu 4
Affiliations

Affiliations

  • 1 Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 110032 Shenyang, China; Research Center for Drug Metabolism, Jilin University, 2699 Qianjin Road, 130012 Changchun, China.
  • 2 Research Center for Drug Metabolism, Jilin University, 2699 Qianjin Road, 130012 Changchun, China.
  • 3 School of Pharmacy, University of Otago, Dunedin, New Zealand.
  • 4 Research Center for Drug Metabolism, Jilin University, 2699 Qianjin Road, 130012 Changchun, China. Electronic address: gujk@mail.jlu.edu.cn.
Abstract

Ethnopharmacological relevance: Adequate pharmacokinetic data of escin, a natural mixture of triterpene saponins used for the treatment of chronic venous insufficiency, hemorrhoids, inflammation and edema, is of special interest in view of the growing use of escin agent in clinical medicine. However, pharmacokinetic data are inadequate to support their clinical indication. Escin Ib and isoescin Ib are the chief active ingredients in escin, pharmacokinetics study of them would be helpful for improving the practice of escin application. The goals of this study are to determine the plasma concentration of escin Ib and isoescin Ib using an established liquid chromatography tandem mass spectrometry (LC-MS/MS) method and to compare the pharmacokinetics and bioavailability of these compounds in rats when administered as pure isomers or as sodium escinate.

Materials and methods: Five groups of Wistar rats (n=6 per group) were treated with either an intravenous (IV) dose (2.78mg/kg) of sodium escinate (corresponding to 0.5mg/kg of escin Ib and 0.5mg/kg of isoescin Ib), an IV dose (0.5mg/kg) and an oral dose (4mg/kg) of pure escin Ib or isoescin Ib. The concentrations of escin Ib and isoescin Ib in rat plasma were determined by LC-MS/MS at various times following the administration of the drugs. The pharmacokinetic parameters were estimated by a non-compartmental analysis and then subjected to statistical analysis.

Results: The administration of sodium escinate, which contains the two isomers, gave rise to higher terminal phase half-life (t1/2) and mean residence time (MRT) values for both escin Ib and isoescin Ib compared to the corresponding compounds administered alone. The absorption of escin Ib and isoescin Ib was very poor, with the oral bioavailability (F) values of <2% observed for both compounds. The two compounds were found to isomerize in vivo, wherein the conversion of escin Ib to isoescin Ib was much easier than that of isoescin Ib to escin Ib.

Conclusions: A comparison of the pharmacokinetics of escin Ib and isoescin Ib administered alone and together in rats suggests that the administration of herbal preparations of escin in a clinical setting may result in a longer duration of action than the administration of each isomer alone. The interconversion of escin Ib and isoescin Ib when administered alone indicates that the administration of one isomer results in exposure to the other isomer.

Keywords

Escin Ib; Isoescin Ib; LC–MS/MS; Pharmacokinetics; Rats; Sodium escinate.

Figures
Products